Exchange: NASDAQ·Updated 07:30 PM EST

About MGTX

About

MeiraGTx Holdings Plc is a clinical-stage genetic medicines company with a broad pipeline of late-stage clinical programs, including Parkinson’s disease, radiation-induced xerostomia and AIPL1-associated retinal dystrophy. It targets local delivery of small doses of genetic medicines to treat both inherited and more common conditions with severe unmet needs. The company was founded on March 20, 2015 and is headquartered in New York, NY.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
403

Frequently Asked Questions

Advertisement|Remove ads.